A Glimpse Into The Expert Outlook On ResMed Through 6 Analysts
Portfolio Pulse from Benzinga Insights
ResMed (NYSE:RMD) has received mixed analyst ratings over the past three months, with a majority being indifferent. Analysts have set a 12-month average price target of $228.17, reflecting a slight increase from previous targets. ResMed's financials show strong net margins and return on equity, but its revenue growth lags behind industry peers.
September 04, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
ResMed has received mixed analyst ratings, with a 12-month average price target of $228.17. The company's financials show strong net margins and return on equity, but its revenue growth is below industry averages.
The mixed analyst ratings suggest a neutral short-term impact on ResMed's stock price. The average price target indicates a slight upward trend, but the company's revenue growth lagging behind peers may offset this. Strong financial metrics like net margins and ROE provide a positive outlook, but the overall sentiment remains balanced.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100